Eli Lilly plans $ 27 billion in new plants because Trump threatens pharmaceutical tariffs | News for production
New plants will be built in the US over the next five years and create 3000 jobs for qualified workers.
Eli Lilly plans to spend at least $ 27 billion to build four new manufacturing facilities in the United States, said a drug manufacturer while struggling with a threat of drug import from Trump administration.
New plants will be built in the next five years, and it is expected to create more than 3000 jobs for qualified workers such as engineers and scientists, as well as 10,000 construction work, a company said at a press conference in Washington on Wednesday.
Lilly said she would announce the sites of the site later this year.
The announcement comes less than a week after US President Donald Trump met with the main managers of the main drug manufacturers, including executive director Lilly David Ricks, to discuss problems in the industry, such as drug import tariffs.
US Secretary of the Howard Lutnick store said at a press conference that Lilly was doing “exactly what the president hoped to happen.”
Ricks said he hoped that the Government would exclude medical supplies from potential tariffs and continue to follow further tax reforms.
The Executive Director said in a statement earlier on Wednesday that the legislation on the reduction of taxes was introduced in Trump’s first term for domestic manufacturer of drug manufacturer.
Increase domestic production
Trump, who has been a campaign on the promise to increase domestic production, has accumulated pressure on medication producers since he took over to move medicine production to the United States. Last week, he suggested that 25 percent of duties could impose on pharmaceutical and other imports.
Other sectors also publish announcements in production. Earlier this week, Apple said he would spend $ 500 billion In the United States for the next four years, but analysts said some of this included current obligations.
The US and his main trade partners agreed that reciprocal tariff elimination for pharmaceutical products and chemicals used in the production of drugs in the last 30 years will be abolished, according to the US Trade Representative’s Office.
Despite the Republicans at the White House meeting earlier this month to think about such an exemption, Trump has yet to be excluded.
Responding to the question of dismissing federal employees in the US Food and Medication Administration, the Executive Director said that Lilly’s fees were going to financing staff at the Agency, and the company would be worried if these funds were “directed at something else”.
Lilly, which became the world’s most respected health company, worth more than $ 855 billion, said she had already committed $ 23 billion in increasing her US product print of 2020. His announcement on Wednesday brings that total number of more than $ 50 billion.
Three Lilly new plants will be used to produce pharmaceutical raw ingredients, while the fourth will make medicines that can be injected, said the drug manufacturer.
